

Press release

Start of clinical trial for Leukocyte Inhibition Module (LIM)

Frankfurt/Main, Germany, October 2005

LEUKOCARE has announced the start of a phase II clinical trial for its proprietary developed product designated Leukocyte Inhibition Module (LIM) to be applied in the field of cardiac surgery. It is a controlled randomized study to investigate the effect of the LIM on inflammatory responses, organ functions and clinical outcome in patients undergoing coronary artery bypass grafting (CABG) with cardiopulmonary bypass.

The LIM is integrated into the perfusion set of the heart lung machine. The anti-inflammatory functionality is achieved by functional antibodies coupled to the surface of the module. These antibodies inactivate neutrophil granulocytes, immune cells being responsible for the innate immune response. By limiting the perioperative inflammation severe clinical manifestations are to be prevented such as atrial fibrillation, pulmonary dysfunction, impaired hemodynamics or brain injuries.

To protect the structure of the sensitive and unstable antibody, LEUKOCARE uses its proprietary Stabilizing Postcoating. This nanocoating technology leads to an increased stress-resistance of functional molecules during standard sterilization procedures and storage.

“I am very proud that we have developed our LIM technology from the first idea up to this stage to start this clinical trial” says Prof. Martin Scholz, CSO of LEUKOCARE. “This study will be a milestone for our company.”

The study will be performed at the University Hospital of Frankfurt/Main, Germany under the responsibility of Prof. Anton Moritz, Director of the Department of Thoracic and Cardiovascular Surgery, as principal investigator. The duration of this study is expected to be about 12 months with 150 patients to be included into the study.

About LEUKOCARE

LEUKOCARE is a product-focused, clinical-stage biotechnology company founded in 2001 and headquartered in Munich, Germany. LEUKOCARE is a

leading solution provider to biofunctionalize surfaces, primarily of medical devices, by its Stabilizing Postcoating technology, allowing the standard sterilization of proteins by e.g. irradiation or ethylene oxide.

By coupling, protecting and – if desirable - eluting biofunctional molecules (e.g. proteins, peptides, small molecules) LEUKOCARE can functionalize a wide variety of surfaces including implant surfaces, wound dressings, patches, stents, catheters, columns for ex-vivo blood treatment and others. These technologies are characterized by their modular versatility and biocompatibility.

LEUKOCARE utilizes its comprehensive biofunctional coating expertise in product-focused industry partnerships. The company offers its know-how in biofunctional coatings and product development to interested parties on a flexible basis ranging from service-based collaborations to co-development partnerships.

For further information please visit our homepage www.leukocare.com or contact us:

Prof. Dr. Martin Scholz

CSO

Phone: +49 (0)89 780 16 65 – 0

Fax: +49 (0)89 780 16 65 – 11

Email: martin.scholz@leukocare.com